Wall Street Zen Downgrades Medtronic (NYSE:MDT) to Hold

Medtronic (NYSE:MDT) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

A number of other equities research analysts have also issued reports on MDT. Evercore set a $106.00 price target on shares of Medtronic and gave the stock an “outperform” rating in a report on Thursday. Sanford C. Bernstein lifted their target price on shares of Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a research note on Friday, January 9th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Medtronic in a research note on Monday, December 29th. William Blair raised shares of Medtronic from a “market perform” rating to an “outperform” rating in a research note on Tuesday, January 6th. Finally, Barclays lifted their target price on shares of Medtronic from $118.00 to $120.00 and gave the company an “overweight” rating in a research note on Wednesday, April 1st. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, Medtronic presently has a consensus rating of “Moderate Buy” and a consensus target price of $109.00.

Medtronic Price Performance

Shares of Medtronic stock opened at $87.17 on Friday. The firm has a market cap of $111.91 billion, a PE ratio of 24.28, a price-to-earnings-growth ratio of 2.28 and a beta of 0.75. Medtronic has a 12-month low of $79.93 and a 12-month high of $106.33. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The company’s fifty day simple moving average is $93.08 and its two-hundred day simple moving average is $95.96.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The business had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company’s revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the firm earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities analysts expect that Medtronic will post 5.46 EPS for the current year.

Insider Buying and Selling at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the sale, the executive vice president owned 32,768 shares of the company’s stock, valued at $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.26% of the company’s stock.

Institutional Investors Weigh In On Medtronic

Hedge funds have recently bought and sold shares of the business. Monetary Solutions Ltd bought a new stake in Medtronic during the fourth quarter worth about $27,000. Corundum Trust Company INC bought a new stake in Medtronic during the third quarter worth about $27,000. Lodestone Wealth Management LLC bought a new stake in Medtronic during the fourth quarter worth about $27,000. Anfield Capital Management LLC boosted its stake in Medtronic by 410.7% during the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 230 shares in the last quarter. Finally, Board of the Pension Protection Fund bought a new stake in Medtronic during the fourth quarter worth about $29,000. Institutional investors own 82.06% of the company’s stock.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).